Gemcitabine is an effective newly developed chemotherapeutic agent, which is increasingly being used to treat non-small cell lung, ovarian and breast cancers. Pulmonary toxicity is usually self-limiting mild dyspnea, bronchospasm, but severe pulmonary toxicity is rarely reported. Herein, we report drug induced interstitial lung disease associated with gemcitabine treatment. High resolution computerized tomogram (HRCT) showed an increased ground glass opacity and thickened septal lines. The patient showed a rapid good response with prednisolone treatment.(Tuberculosis and Respiratory Diseases 2004, 56:315-320)
(1994) Gemcitabine:current status of phase I and II trials,
(1994) Single agent activity of weekly gemcitabine in advanced non- small cell lung cancer:a phase II study,
(1995) Advanced breast cancer: a phase II trial with gemcitabine,
(1995) Dyspnoea with gemcitabine is commonly seen, often disease related, transient and rarely severe,
(1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine,
(1998) Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy,
(1998) Diffuse alveolar damage in a patient treated with gemcitabine,
(2002) Severe pulmonary toxicity in a patient treated with gemcitabine,
(2000) Gemcitabine pulmonary toxicity : CT features,
(1990) Fatal pulmonary failure complicating high-dose cytosine arabiꠀnoside therapy in acute leukemia,
(1985) Subacute pulmonary failure complicating therapy with high dose ara-C in acute leukemia,
(1997) Drugs that may injure the respiratory system,
(1981) Ara-C Lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia,